Avricore Health (AVCRF) EBITDA (2009 - 2025)

Avricore Health has disclosed EBITDA across 17 years of filings, most recently posting -$275431.0 for Q3 2025.

• In Q3 2025, EBITDA fell 109.83% year-over-year to -$275431.0; the TTM figure through Sep 2025 stood at -$792332.3 (down 1128.02% YoY), while the FY2025 annual figure was -$1.3 million, down 172.26% from the prior year.
• EBITDA improved to -$275431.0 in Q3 2025, from -$331765.5 in the prior quarter.
• Over the last five years, EBITDA for AVCRF reached as high as $565162.6 in Q1 2021 and fell as low as -$331765.5 in Q2 2025.
• The 5-year median for EBITDA is -$134791.8 (2022), against an average of -$23196.4.
• Annual changes were most pronounced in 2021 — EBITDA surged 228.63% — and 2025, when it sank 939.96%.
• A 5-year view of EBITDA shows it stood at $165723.9 in 2021, then sank by 208.82% to -$180336.8 in 2022, then surged by 124.27% to $43766.6 in 2023, then sank by 399.92% to -$131264.2 in 2024, then plunged by 109.83% to -$275431.0 in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$275431.0, -$331765.5, and -$53871.6 for Q3 2025, Q2 2025, and Q1 2025 respectively.